EF Hutton Initiates Coverage On Enlivex Therapeutics with Buy Rating, Announces Price Target of $13
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on Enlivex Therapeutics with a Buy rating and set a price target of $13.
August 27, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on Enlivex Therapeutics with a Buy rating and a price target of $13, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by EF Hutton suggests a positive sentiment towards Enlivex Therapeutics. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100